Dimerix (ASX:DXB) share price rockets 50% on capital raise and results

The biopharmaceutical company is progressing on numerous clinical trials.

The Dimerix Ltd (ASX: DXB) share price is skyrocketing in late morning trade, up 50% to 35 cents per share.

This comes as the biopharmaceutical company emerges from Thursday's trading halt, announcing a successful capital raising and releasing its full 2021 financial year results.

First, let's look at the results for the year ended 30 June.

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition

Image source: Getty Images

Dimerix share price soars despite operating losses

  • Revenues from ordinary activities decreased 44% year-on-year
  • Loss after providing for income tax of $6.37 million, up from a loss of $4.49 million in FY20
  • Cash reserve of $5.3 million
  • No dividends paid during FY21

What happened in FY21 for Dimerix

Dimerix reported it demonstrated "favourable clinical efficacy and strong safety profiles" across a number of its Phase 2 renal clinical studies

In the United States, the Food and Drug Administration (FDA) gave clarity to the company's Focal Segmental Glomerulosclerosis (FSGS) and Orphan Drug Designation, accelerating the approval pathway. Similar approvals were granted by the United Kingdom and European Union medical authorities.

The company also has 2 independent Phase 3 clinical studies currently underway in patients with COVID-19 respiratory complications.

Additionally, Dimerix reported its DMX-200 manufacturing process was optimised to improve commercial scalability and global logistics.

What did management say?

Dimerix's CEO Nina Webster said:

We faced a year of challenges and opportunities in 2020. I am enormously proud of how adaptive and resilient our employees were in the face of a global pandemic and am grateful for their unwavering commitment to deliver on strategy and further strengthen the pipeline.

Research & development director Robert Shepherd added:

It has been a very exciting and rewarding year, with our Phase 2 studies in FSGS and diabetic kidney disease providing robust data to progress into a global Phase 3 study that may provide a much-needed therapeutic option for patients with FSGS. The outcomes from our DMX-200 studies have supported inclusion into two COVID programs and I am pleased to be in a position support the global effort in treating the effects of this disease.

What's next for Dimerix

Looking ahead, the company plans include:

  • Global FSGS Phase 3 clinical study initiation
  • REMAP-CAP Phase 3 study in intensive care COVID-19 patients conclusion
  • CLARITY 2.0 Phase 3 study in hospitalised COVID-19 patients conclusion
  • DMX-700 pre-clinical study initiation
  • DMX-200 in diabetic kidney disease longer term study initiation

Today's capital raising announcement

Circling back to the cap-raise, which could also be influencing the Dimerix share price lift today, the company said it has received firm commitments to raise $20 million via a 2-tranche placement of some 100 million new shares.

Commenting on the capital raising, Webster said:

The company will emerge from this capital raise with a substantially strengthened balance sheet, putting us in a great position to deliver on the Dimerix pipeline, including the Phase 3 programs in FSGS as well as in COVID-19 patients with respiratory complications. We look forward to reporting on our progress in due course.

The Dimerix share price is up 38% in 2021.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Doctor with stethoscope typing on her computer.
Healthcare Shares

$128 million contract win: Are Pro Medicus shares a strong buy?

I remain a fan of this healthcare technology company, and today's announcement gives me another reason to be optimistic.

Read more »

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »